文摘
Age is one of the most important prognostic factors in glioblastoma patients, but no standard treatment has been established for elderly patients with this condition. We therefore conducted a retrospective cohort study to evaluate treatment regimens and outcomes in elderly glioblastoma patients. The study population consisted of 79 glioblastoma patients aged ?6?years (median age 78.0?years; 34 men and 45 women). The median preoperative Karnofsky performance status (KPS) score was 60. Surgical procedures were classified as biopsy (31 patients, 39.2?%), <95?% resection of the tumor (21 patients, 26.9?%), and ?5?% resection of the tumor (26 patients, 33.3?%). Sixty-seven patients (81.0?%) received radiotherapy and 45 patients (57.0?%) received chemotherapy. The median overall progression-free survival time was 6.8?months, and the median overall survival time was 9.8?months. Patients aged ?8?years were significantly less likely to receive radiotherapy (p?=?0.004). Patients with a postoperative KPS score of ?0 were significantly more likely to receive maintenance chemotherapy (p?=?0.008). Multivariate analyses identified two independent prognostic factors: postoperative KPS score ?0 (hazard ratio [HR]?=?0.531, 95?% confidence interval [CI] 0.315-.894, p?=?0.017) and temozolomide therapy (HR?=?0.442, 95?% CI 0.25-.784, p?<?0.001).The findings of this study suggest that postoperative KPS score is an important prognostic factor for glioblastoma patients aged ?6?years, and that these patients may benefit from temozolomide therapy.